News

Palantir Shares Tumble After Monster Rally as Wall Street Turns Cautious Before Q2 Results

Visa shares rally on plans to lower its global headcount by 7%. Here’s how you should play V stock ahead of the company’s Q3 earnings today after market close.

Wireless chips maker Skyworks Solutions (NASDAQ: SWKS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 3.1% year on year to $934.8 million. Guidance for next quarter’s revenue was better than expected at $1.04 billion at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $1.08 per share was 4.8% above analysts’ consensus estimates.

US equity indexes were mixed Tuesday as crude oil prices fell and semiconductor stocks led a pullbac

Communications chips maker Qorvo (NASDAQ: QRVO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 4.2% year on year to $784.8 million. Its non-GAAP profit of $1.64 per share was 54.1% above analysts’ consensus estimates.

Is this a golden buying opportunity for the AI beneficiary?

AI Chip Stocks Under Pressure as China Competition and Funding Fears Hit Sector

3X'ing the risk on semiconductor stocks turned out to be a bad bet today.

UPS beat expectations, but the market has concerns over operating margins and U.S. Domestic segment performance.

Dell Stock Tumbles After Analyst Warns of AI Server Risks

Exxon Mobil's (XOM) stock offers limited upside potential amid ongoing geopolitical concerns, while

It’s a chip panic that “appears to be indiscriminate,” analysts say.

Trading volumes on the Robinhood (NASDAQ: $HOOD) Chain platform are slumping as investor interest in memecoins fade...

Microsoft stock headed higher Tuesday, building on two straight advances as investors awaited the tech heavyweight's fourth-quarter earnings report due Wednesday. Is Microsoft stock a buy or sell now? Coming into Tuesday's session, the stock had risen more than 10% from its June lows and was running into its 50-day moving average.

Core Scientific will initially provide more than 500 megawatts of AI-ready capacity beginning in 2027.

Tech stocks were lower late Tuesday afternoon, with the State Street Technology Select Sector SPDR E

Micron stock tumbled 9% as a perfect storm hit the chip sector. Here's what you need to know.

Micron stock was among the sharpest fallers Tuesday after being spared the worst of the selling in the previous session. Micron stock was down 9% by midafternoon, while Sandisk Western Digital and Advanced Micro Devices were down around 15%, 8.2%, and 7.9%, respectively. The Nasdaq Composite was mostly flat despite the chaos.

Microsoft and Meta both crushed their last quarters, yet Wall Street's real verdict on July 29 has nothing to do with revenue beats. The question traders are actually pricing is which AI capex monster blinks first.

Commvault beat earnings estimates and posted 71% free cash flow growth. So why did the stock crash 20%?

On Tuesday the tech giant launched Apple Upgrade, a new program from a partnership with ‘buy now, pay later’ service Klarna.

B. Riley stated near-term challenges, including weakness in communications, program delays, and pressure from AI sentiment, could create volatility for the stock.

Corning's third-quarter sales forecast missed expectations despite continued demand for AI data-center infrastructure.

Tech stocks were lower Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (X

Hilton raised its RevPAR forecast, but regional weakness and fourth-quarter pressures weighed on investor sentiment.

Recent pullbacks in technology and semiconductor stocks reflect market normalization and profit-taking rather than a fundamental shift in the artificial intelligence thesis, according to JPMorgan.

Snowflake stock gapped up 37% on earnings in May before forming a cup-with-handle base that offers an entry at 279.49.

The two memory-chip leaders helped pull South Korea's KOSPI down 10.8% during Tuesday's regional semiconductor rout.

The brokerage says China’s progress in DUV lithography poses only a limited financial risk and sees the recent selloff as a buying opportunity.

Replimune (NASDAQ: REPL) shares fell nearly 31% on Tuesday after US Food and Drug Administration (FDA) staff reviewers raised concerns over the effectiveness of the company’s lead cancer therapy, RP1, ahead of a key advisory committee meeting. The decline followed the release of FDA briefing...